» Articles » PMID: 39478498

Proteomic Analysis of Plasma Total Exosomes and Placenta-derived Exosomes in Patients with Gestational Diabetes Mellitus in the First and Second Trimesters

Overview
Publisher Biomed Central
Date 2024 Oct 31
PMID 39478498
Authors
Affiliations
Soon will be listed here.
Abstract

Gestational diabetes mellitus (GDM) is the first spontaneous hyperglycemia during pregnancy. Early diagnosis and intervention are important for the management of the disease. This study compared and analyzed the proteins of total plasma exosomes (T-EXO) and placental-derived exosomes (PLAP-EXO) in pregnant women who subsequently developed GDM (12-16 weeks), GDM patients (24-28 weeks) and their corresponding controls to investigate the pathogenesis and biomarkers of GDM associated with exosomes. The exosomal proteins were extracted and studied by proteomics approach, then bioinformatics analysis was applied to the differentially expressed proteins (DEPs) between the groups. At 12-16 and 24-28 weeks of gestation, 36 and 21 DEPs were identified in T-EXO, while 34 and 20 DEPs were identified in PLAP-EXO between GDM and controls, respectively. These proteins are mainly involved in complement pathways, immunity, inflammation, coagulation and other pathways, most of them have been previously reported as blood or exosomal proteins associated with GDM. The findings suggest that the development of GDM is a progressive process and that early changes promote the development of the disease. Maternal and placental factors play a key role in the pathogenesis of GDM. These proteins especially Hub proteins have the potential to become predictive and diagnostic biomarkers for GDM.

References
1.
Engstrom G, Hedblad B, Eriksson K, Janzon L, Lindgarde F . Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. 2005; 54(2):570-5. DOI: 10.2337/diabetes.54.2.570. View

2.
Volpe L, Di Cianni G, Lencioni C, Cuccuru I, Benzi L, Del Prato S . Gestational diabetes, inflammation, and late vascular disease. J Endocrinol Invest. 2007; 30(10):873-9. DOI: 10.1007/BF03349231. View

3.
Zhang H, Zhao Y, Zhao D, Chen X, Khan N, Liu X . Potential biomarkers identified in plasma of patients with gestational diabetes mellitus. Metabolomics. 2021; 17(11):99. DOI: 10.1007/s11306-021-01851-x. View

4.
Shen L, Zhang H, Lin J, Gao Y, Chen M, Khan N . A Combined Proteomics and Metabolomics Profiling to Investigate the Genetic Heterogeneity of Autistic Children. Mol Neurobiol. 2022; 59(6):3529-3545. DOI: 10.1007/s12035-022-02801-x. View

5.
Ling Y, Su J, Lin J, Wang S . Screening of serum biomarkers of preeclampsia by proteomics combination with bioinformatics. Hypertens Pregnancy. 2019; 38(3):184-192. DOI: 10.1080/10641955.2019.1640246. View